Medically reviewed by Edmund Khoo, DDS Thrush, or oral candidiasis, is a fungal infection in your mouth and throat. It is ...

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data ...

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted ...

Investment analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of SCYNEXIS in a report issued on Thursday, March 13th. Brookline Capital Management analyst K.

Further information The NICE-Wide Prioritisation Board have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected for evaluation.

SCYNEXIS (NASDAQ:SCYX – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday. SCYNEXIS Stock Up 8.6 % ...

Antibiotics increase the gut oxygen levels and favor growth of harmful fungi. Chemically restoring intestinal gut hypoxia ...

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company revolutionizing ...

The anti-inflammatory properties of probiotics found in DentPure are vital for promoting gum strength. By reducing ...